Axitinib is an inhibitor of VEGFR that exhibits anticancer chemotherapeutic and anti-angiogenic activities. Axitinib is currently in clinical trials as a potential treatment for renal cell carcinoma. In vitro, axitinib increases levels of CD8+ T cells and decreases levels of myeloid-derived suppressor cells, inhibiting proliferation and increasing apoptosis. In vivo, this compound inhibits expression of iNOS, arginase, IL-6, TNF-?, and IFN-?, increasing apoptosis and inhibiting tumor growth. In animal models of lung adenocarcinoma, axitinib decreases tumor vasculature and lesion growth.
Popular test
Uniformity of Dosage Units
Allschoolabs
Uniformity of Dosage Units is a specialised analytical laboratory service that assesses whether individual dosage units contain sufficiently consis...
![ANTI D TITRE – [Serum]](https://app.analysisafrica.com/backend/uploads/tests/images/1754385122_6891cae238432.jpg)
No products in the cart.